Ontology highlight
ABSTRACT:
SUBMITTER: Erbe AK
PROVIDER: S-EPMC5754221 | biostudies-literature | 2018 Jan
REPOSITORIES: biostudies-literature
Erbe Amy K AK Wang Wei W Carmichael Lakeesha L Kim KyungMann K Mendonça Eneida A EA Song Yiqiang Y Hess Dustin D Reville Patrick K PK London Wendy B WB Naranjo Arlene A Hank Jacquelyn A JA Diccianni Mitchell B MB Reisfeld Ralph A RA Gillies Stephen D SD Matthay Katherine K KK Cohn Susan L SL Hogarty Michael D MD Maris John M JM Park Julie R JR Ozkaynak M Fevzi MF Gilman Andrew L AL Yu Alice L AL Sondel Paul M PM
Clinical cancer research : an official journal of the American Association for Cancer Research 20171002 1
<b>Purpose:</b> In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy regimen of dinutuximab, GM-CSF, IL2, and isotretinoin compared with treatment with isotretinoin alone. Dinutuximab, a chimeric anti-GD2 monoclonal antibody, acts in part via natural killer (NK) cells. Killer immunoglobulin-like receptors (KIR) o ...[more]